Zacks Research Brokers Lift Earnings Estimates for APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Monday, June 30th. Zacks Research analyst R. Department now forecasts that the company will earn ($0.43) per share for the quarter, up from their previous forecast of ($0.44). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($2.03) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.69) EPS and FY2027 earnings at ($0.43) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). The company had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.54) earnings per share.

A number of other equities analysts have also commented on the stock. Royal Bank Of Canada reduced their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research report on Thursday, May 8th. Raymond James Financial downgraded Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $75.00 to $52.00 in a report on Friday, May 9th. Scotiabank decreased their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company increased their price target on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Monday, June 2nd. Finally, Citigroup decreased their price objective on Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating for the company in a report on Thursday, May 22nd. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.79.

Apellis Pharmaceuticals Trading Up 0.9%

Shares of APLS opened at $17.99 on Wednesday. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -10.05 and a beta of 0.67. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $42.47. The company has a 50-day moving average of $18.14 and a 200 day moving average of $23.70.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas grew its stake in shares of Apellis Pharmaceuticals by 9.4% during the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company’s stock worth $691,000 after acquiring an additional 1,864 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Apellis Pharmaceuticals by 2.6% in the 4th quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company’s stock worth $28,170,000 after purchasing an additional 22,507 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Apellis Pharmaceuticals by 147.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 74,325 shares of the company’s stock worth $1,625,000 after purchasing an additional 44,332 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Apellis Pharmaceuticals by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company’s stock worth $6,793,000 after purchasing an additional 21,822 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Apellis Pharmaceuticals by 1,795.4% during the 1st quarter. GAMMA Investing LLC now owns 10,235 shares of the company’s stock valued at $224,000 after purchasing an additional 9,695 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,000 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $18.77, for a total value of $93,850.00. Following the completion of the sale, the general counsel owned 133,730 shares of the company’s stock, valued at $2,510,112.10. This trade represents a 3.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).